A Phase 2 interventional study of OPA-15406 and Placebo in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-07-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 4th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 15 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2016.
This study's enrollment of 200 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd.: 2 open now, 2 under way, 2 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 4th registered.
Otsuka Holdings Co., Ltd.’s Dermatitis, Atopic studies by the year they started, since 2012.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 13 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
Drug: OPA-15406
Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
Drug: OPA-15406
Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Drug: Placebo
Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4
The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.
Time frame: At Week 4
Change From Baseline in Eczema Area and Severity Index (EASI) Score
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
Time frame: Baseline, Week 4
Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score
The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects will mark the point of pruritus intensity during the last 24 hours on the line of a 100- mm VAS sheet between the left end (no pruritus: the score is 0 ) and the right end (very severe pruritus: the score is 100), and a negative change from the baseline means improvement and a positive change means worsening. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded
Time frame: Baseline, Week 4
Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score
The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
Time frame: Baseline, Hour 156
Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score
The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
Time frame: Baseline, Week 4
Change From Baseline in Percentage Affected Body Surface Area
The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA.
Time frame: Baseline, Week 4
Mean (SD) OPA-15406 Plasma Trough Concentrations
The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration. Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.
Time frame: Week1, Week4, Week8
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA
The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.
Time frame: Week1, Week4, Week8
OPA-15406 Plasma PK Parameters, Cmax
OPA-15406 plasma PK parameter (Cmax) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.
Time frame: Day 1 and Week 4
OPA-15406 Plasma PK Parameters, AUC8h
OPA-15406 plasma PK parameter (AUC8h) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.
Time frame: Day 1 and Week 4
| Milestone | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Started | 67 | 67 | 66 |
| Completed | 46 | 53 | 46 |
| Not completed | 21 | 14 | 20 |
| Withdrew: Adverse event | 15 | 7 | 15 |
| Withdrew: Physician decision | 2 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 4 |
| Withdrew: >40% of body surface area | 0 | 1 | 1 |
The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.
| percentage of participants | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4 | 14.93 (7.40 to 25.74) | 22.39 (13.11 to 34.22) | 9.09 (3.41 to 18.74) |
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
| score on a scale | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Eczema Area and Severity Index (EASI) Score | -2.32 ± 0.75 | -3.16 ± 0.75 | -0.15 ± 0.77 |
The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects will mark the point of pruritus intensity during the last 24 hours on the line of a 100- mm VAS sheet between the left end (no pruritus: the score is 0 ) and the right end (very severe pruritus: the score is 100), and a negative change from the baseline means improvement and a positive change means worsening. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded
| mm | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score | -6.76 ± 3.31 | -6.28 ± 3.32 | 0.90 ± 3.24 |
The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
| score on a scale | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score | -0.43 ± 0.10 | -0.49 ± 0.10 | -0.06 ± 0.10 |
The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
| score on a scale | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score | -1.36 ± 0.77 | -2.90 ± 0.76 | -0.02 ± 0.79 |
The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA.
| percentage of Affected Body Surface Area | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage Affected Body Surface Area | -3.94 ± 1.44 | -3.73 ± 1.43 | -0.32 ± 1.48 |
The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration. Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.
| ng/mL/mg | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Week 1 | 1.74 ± 1.87 | 4.96 ± 5.04 |
| Week 4 | 1.71 ± 2.50 | 5.22 ± 4.70 |
| Week 8 | 1.51 ± 1.77 | 5.52 ± 8.28 |
The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.
| ng/mL/mg | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Week 1 | 0.114 ± 0.0991 | 0.113 ± 0.0952 |
| Week 4 | 0.104 ± 0.119 | 0.127 ± 0.119 |
| Week 8 | 0.0910 ± 0.103 | 0.137 ± 0.242 |
OPA-15406 plasma PK parameter (Cmax) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.
| ng/mL | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Day 1 | 4.01 ± 5.90 | 7.27 ± 6.42 |
| Week 4 | 2.07 ± 1.47 | 10.4 ± 3.68 |
OPA-15406 plasma PK parameter (AUC8h) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.
| ng・h/mL | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Day 1 | 22.0 ± 34.7 | 41.6 ± 37.6 |
| Week 4 | 11.6 ± 7.23 | 65.2 ± 26.8 |
Collected over Treatment period (8 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.3% OPA-15406 | 0/67 (0%) | 0/67 (0%) | 22/67 (32.8%) |
| 1% OPA-15406 | 0/67 (0%) | 0/67 (0%) | 11/67 (16.4%) |
| Placebo | 0/66 (0%) | 0/66 (0%) | 20/66 (30.3%) |
| Event | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 11/67 | 6/67 | 12/66 |
| Viral upper respiratory tract infectionInfections and infestations | 7/67 | 4/67 | 7/66 |
| PruritusSkin and subcutaneous tissue disorders | 5/67 | 1/67 | 4/66 |
| Age, Categorical(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 2 | 0 | 1 | 3 |
| Between 18 and 65 years | 65 | 67 | 65 | 197 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Mean | 30.2 ± 9.0 | 31.0 ± 10.8 | 31.6 ± 10.0 | 30.9 ± 9.9 |
| Sex: Female, Male(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Female | 22 | 25 | 23 | 70 |
| Male | 45 | 42 | 43 | 130 |
| Race/Ethnicity, Customized(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Japanese | 67 | 67 | 66 | 200 |
| Region of Enrollment(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Japan | 67 | 67 | 66 | 200 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Jun 2017, 9 months.
Results were first posted in Jun 2020, 3 years after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast
Otsuka Pharmaceutical Co., Ltd. →